Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions ...Middle East

TITUSVILLE, N.J., March 19, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to...

Hence then, the article about janssen announces u s fda approval of ponvory ponesimod an oral treatment for adults with relapsing multiple sclerosis proven superior to aubagio teriflunomide in reducing annual relapses and brain lesions was published today ( Friday 19/03/2021 - 03:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Announces U.S. FDA Approval of PONVORY™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions )

Also on site :

• The Stars of 1982’s Most Beloved Film Flop, ‘Grease 2,’ Just Reunited on the Red Carpet
• This New Doritos Snack Just Landed at Costco
• Amazon Has a 'Timeless' $27 Lee Denim Jacket That Shoppers Call a 'Must-Have Staple'